QC
GILD icon

QCM Cayman’s Gilead Sciences GILD Stock Holding History

QCM Cayman’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-27,400
Closed -$1.86M – 249
2017
Q1 		$1.86M Buy
+27,400
New +$1.93M 0.35% 71
2016
Q3 		– Sell
-8,800
Closed -$734K – 255
2016
Q2 		$734K Buy
+8,800
New +$781K 0.32% 41
2015
Q4 		– Sell
-8,700
Closed -$854K – 196
2015
Q3 		$854K Buy
8,700
+3,500
+67% +$389K 0.29% 33
2015
Q2 		$609K Buy
+5,200
New +$568K 0.23% 61
2015
Q1 		– Sell
-10,200
Closed -$1.08M – 231
2014
Q4 		$1.08M Buy
10,200
+5,500
+117% +$569K 0.45% 39
2014
Q3 		$500K Buy
+4,700
New +$460K 0.12% 75

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QCM Cayman's GILD Position: Q4 2017 in Review

QCM Cayman sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 4,952 shares — an estimated $401K sold.

QCM Cayman first reported a position in GILD in Q1 2014 and held it in 10 quarters. The position peaked at $843K in Q4 2014. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

  • QCM Cayman reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
  • QCM Cayman sold 4,952 Gilead Sciences shares in Q4 2017, an estimated $401K.
  • QCM Cayman first reported a position in Gilead Sciences in Q1 2014 and held it in 10 quarters.
  • QCM Cayman's Gilead Sciences position peaked at $843K in Q4 2014.
  • 1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on QCM Cayman's 13F filing for Q4 2017, filed 14 Feb 2018.